# Strategies for Diagnosing and Treating Disseminated Methicillin-Sensitive Staphylococcus aureus Infections: Insights From a Pustular Eruption

**Authors:** Kritin K Verma, Ethan J Matthew, Ryan Wealther, Rohan Pendse, Michelle Tarbox

PMC · DOI: 10.7759/cureus.67516 · Cureus · 2024-08-22

## TL;DR

A case study shows how a rare skin eruption in an immunocompromised patient led to the diagnosis and treatment of a severe MSSA infection.

## Contribution

This report adds to the limited literature on disseminated staphylococcal infections presenting as vesiculopustular eruptions in immunocompromised individuals.

## Key findings

- Disseminated MSSA infection was diagnosed through clinicopathologic correlation in an immunocompromised patient.
- Prompt identification and treatment with antibiotics and port removal led to clinical improvement.
- Vesiculopustular eruptions are a rare presentation of MSSA and require timely intervention to prevent complications.

## Abstract

A 63-year-old immunocompromised male with a history of renal transplant and stage III large B-cell non-Hodgkin lymphoma undergoing rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy presented with fever and a disseminated pustular eruption. Initial laboratory values indicated septicemia. Differential diagnoses included Sweet’s syndrome, septic emboli, and leukocytoclastic vasculitis. Punch biopsies and bacterial cultures confirmed disseminated methicillin-sensitive Staphylococcus aureus (MSSA) infection. Histopathology revealed intraepidermal vesiculopustules and bacterial cocci colonies in the superficial dermis, suggesting hematogenous spread. The patient’s indwelling venous access port was identified as the infection source and removed. Treatment included antibiotics such as cefepime, vancomycin, fluconazole, and acyclovir, as well as filgrastim for neutropenia. Following port removal and a four-week course of ceftriaxone, the patient’s condition improved. This case highlights the importance of clinicopathologic correlation in diagnosing and managing disseminated staphylococcal infections in immunocompromised patients. The rare presentation of vesiculopustular eruptions secondary to MSSA emphasizes the need for prompt identification and treatment to prevent severe complications. This report contributes to the limited literature on disseminated staphylococcal infections presenting as vesiculopustular eruptions in immunocompromised individuals.

## Linked entities

- **Chemicals:** cyclophosphamide (PubChem CID 2907), doxorubicin (PubChem CID 31703), vincristine (PubChem CID 5978), prednisone (PubChem CID 5865), cefepime (PubChem CID 5479537), vancomycin (PubChem CID 14969), fluconazole (PubChem CID 3365), acyclovir (PubChem CID 135398513), ceftriaxone (PubChem CID 5479530)
- **Diseases:** leukocytoclastic vasculitis (MONDO:0006794), neutropenia (MONDO:0001475)

## Full-text entities

- **Diseases:** leukocytoclastic vasculitis (MESH:C535509), septic emboli (MESH:D020766), septicemia (MESH:D018805), Sweet's syndrome (MESH:D016463), MSSA (MESH:D013203), Pustular Eruption (MESH:D003875), fever (MESH:D005334), stage III large B-cell non-Hodgkin lymphoma (MESH:D016393), infection (MESH:D007239), neutropenia (MESH:D009503)
- **Chemicals:** cefepime (MESH:D000077723), fluconazole (MESH:D015725), vancomycin (MESH:D014640), R-CHOP (-), ceftriaxone (MESH:D002443), acyclovir (MESH:D000212)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11416146/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11416146/full.md

## References

8 references — full list in the complete paper: https://tomesphere.com/paper/PMC11416146/full.md

---
Source: https://tomesphere.com/paper/PMC11416146